Business · 20/11/20261 min read
SRX Global Provides Update on Engineered T-Cell Strategy Following Pfizer–Starna Licensing Agreement
Summary
Pfizer’s $330 million upfront commitment to three pre-IND in vivo CAR-T programs highlights pharmaceutical industry interest in next-generation engineered T-cell platforms